CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $17.69M, lower than 95% of all stocks globally
- PositionCurrent ratio is 25.38×, higher than 95% of its Medical Devices peers (median 3.87×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
3.48BCNY518.87M · vs all stocks (USD)
Revenue (TTM)
118.52MCNY17.69M · vs all stocks (USD)
Profit Margin
-54.87%vs Medical Devices peers
Beta
0.6190xvs all stocks
52-Week Change
-22.12%vs all stocks
Market Capitalization
3.48BCNY518.87M · vs all stocks (USD)
Enterprise Value
354.34MCNY52.89M · vs all stocks (USD)
Price to Sales (TTM)
27.44xvs Medical Devices peers
Price to Book (MRQ)
0.9608xvs Medical Devices peers
Enterprise to Revenue
2.99xvs Medical Devices peers
Enterprise to EBITDA
-15.03xvs Medical Devices peers
Gross Margin
61.60%vs Medical Devices peers
Profit Margin
-54.87%vs Medical Devices peers
Operating Margin
-66.83%vs Medical Devices peers
Return on Assets (TTM)
-1.46%vs Medical Devices peers
Return on Equity (TTM)
-1.94%vs Medical Devices peers
Revenue (TTM)
118.52MCNY17.69M · vs all stocks (USD)
Revenue per Share (TTM)
0.6960CNYUpdated Sep 22, 2026Quarterly Revenue Growth
1.50%vs Medical Devices peers
Gross Profit (TTM)
87.65MCNY13.08M · vs all stocks (USD)
EBITDA (TTM)
18.55MCNY2.77M · vs all stocks (USD)
Net Income (TTM)
-65.04MCNY-9.71M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-12.96%vs Medical Devices peers
Operating Cash Flow (TTM)
52.63MCNY7.86M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
10.24MCNY1.53M · vs all stocks (USD)
Payout Ratio
0.00%vs Medical Devices peers
Revenue
124.82MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
44.74MCNYFY2025 · Dec 31, 2025Gross Profit
80.08MCNYFY2025 · Dec 31, 2025Operating Income
-95.84MCNY-14.31M · vs all stocks (USD)
Pre-tax Income
-42.12MCNYFY2025 · Dec 31, 2025Income Tax Expense
-7.82MCNYFY2025 · Dec 31, 2025Net Income
-34.30MCNYFY2025 · Dec 31, 2025EBIT
-38.63MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
18.55MCNYFY2025 · Dec 31, 2025Research & Development
50.87MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
41.44MCNYFY2025 · Dec 31, 2025Other Operating Expenses
1.24MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
62.07MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.49MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1900CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
180.51MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
180.51MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-34.30MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
23.32MCNYFY2025 · Dec 31, 2025Free Cash Flow
21.95MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.55BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-34.30MCNYFY2025 · Dec 31, 2025Other Non-cash Items
27.16MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
27.88MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.58MCNYFY2025 · Dec 31, 2025Capital Expenditures
-1.37MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.42BCNYFY2025 · Dec 31, 2025Sale of Investments
1.12BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-306.72MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
297.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.98MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-3.03MCNYFY2025 · Dec 31, 2025Other Financing Charges
-261.34MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
29.64MCNYFY2025 · Dec 31, 2025Shares Outstanding
192.16MSharesUpdated Sep 22, 2026Float Shares
98.42MSharesUpdated Sep 22, 2026% Held by Insiders
42.22%vs all stocks
% Held by Institutions
4.39%vs all stocks
Total Cash (MRQ)
2.79BCNY417.11M · vs all stocks (USD)
Total Cash per Share (MRQ)
16.13CNYUpdated Sep 22, 2026Total Debt (MRQ)
292.81MCNY43.71M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0898xvs Medical Devices peers
Current Ratio (MRQ)
25.38xvs Medical Devices peers
Book Value per Share (MRQ)
17.83CNYUpdated Sep 22, 2026Total Assets
3.76BCNY561.82M · vs all stocks (USD)
Total Current Assets
2.99BCNYFY2025 · Dec 31, 2025Total Liabilities
414.95MCNYFY2025 · Dec 31, 2025Total Non-current Assets
777.60MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
288.37MCNYFY2025 · Dec 31, 2025Total Current Liabilities
126.58MCNYFY2025 · Dec 31, 2025Cash
2.55BCNYFY2025 · Dec 31, 2025Cash Equivalents
1.87MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.55BCNYFY2025 · Dec 31, 2025Other Short-term Investments
347.89MCNYFY2025 · Dec 31, 2025Accounts Receivable
31.24MCNYFY2025 · Dec 31, 2025Inventory
45.57MCNYFY2025 · Dec 31, 2025Accounts Payable
55.40MCNYFY2025 · Dec 31, 2025Short-term Debt
11.74MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.05MCNYFY2025 · Dec 31, 2025Long-term Debt
287.23MCNYFY2025 · Dec 31, 2025Common Stock (Book)
192.16MCNYFY2025 · Dec 31, 2025Retained Earnings
1.31BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.35BCNY499.88M · vs all stocks (USD)
Treasury Stock
294.44MCNYFY2025 · Dec 31, 202552-Week Low
14.64CNYUpdated Sep 22, 202652-Week High
28.58CNYUpdated Sep 22, 202652-Week Change
-22.12%vs all stocks
Beta
0.6190xvs all stocks
50-Day MA
16.67CNYUpdated Sep 22, 2026200-Day MA
19.08CNYUpdated Sep 22, 2026Avg 10-Day Volume
1.25MSharesUpdated Sep 22, 2026Avg 30-Day Volume
2.23MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.3700CNYUpdated Sep 22, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 25.38×, higher than 95% of its Medical Devices peers (median 3.87×)Significant
Current ratio: 25.38Industry median: 3.87Industry P95: 12.55Peers compared: 102
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 27.44Revenue Growth YoY: 0.01
High gross margins eroded by operating costsNotable
Gross Margin: 0.62Profit Margin: -0.55
Financial Health
Altman Z-Score 6.43: safe zoneNotable
Altman Z-Score: 6.43
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $17.69M, lower than 95% of all stocks globallySignificant
Revenue (USD): 17,692,044.044Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Aim Vaccine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Crescent Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eiken Chemical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sd Biosensor Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tactile Systems Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Careray Digital Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oculis Holding AG
Tier 1ProductionApproval-Gated PipelineRule
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Hanbon Science & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Succeeder Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
AP Biosciences Inc.
3 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Der Future Science & Technology Co., Ltd.
3 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Shenzhen Sinovatio Technology Co., Ltd.
3 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration